// App-Quantinova.ai

POS1026 (2021) : GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND NON-WORK ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS THROUGH 1 YEAR OF A PHASE 3 TRIAL

Researchers

Presenter

  • J. Curtis

Principal Investigators

  • I. Mcinnes

  • S. Peterson

  • P. Agarwal

  • F. Yang

  • A. Kollmeier

  • E. C. Hsia

  • C. Han

  • W. Tillett

  • P. J. Mease

  • P. Rahman

Medical Centers

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

  • , Janssen Global Services, LLC, Horsham, PA, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Janssen Research & Development, LLC, Immunology, San Diego, CA, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • University of Pennsylvania School of Medicine, Immunology, Philadelphia, United States of America

  • Royal National Hospital for Rheumatic Diseases, Department of Pharmacy & Pharmacology Centre for Therapeutic Innovation, Bath, United Kingdom

  • Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Rheumatology Research, Seattle, United States of America

  • Memorial University of Newfoundland, Craig L Dobbin Genetics Research Centre, St John’s, Canada

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved